Abu Dhabi:Mubadala Bio's Integrated Distribution Solutions (IDS) and GlaxoSmithKline (GSK) have announced a strategic partnership to enhance the availability of GSK's general medicines across the United Arab Emirates (UAE). This alliance aims to support the UAE's healthcare objectives, bolster resilience, and contribute to the development of a top-tier life sciences ecosystem.
According to Wam, the agreement was formalized by Khalid Alkaf, General Manager - Pharma Logistics at Mubadala Bio, and Boyd Chongphaisal, Vice President and General Manager of GSK Gulf. The signing was witnessed by Hamad Almarzooqi, Group Deputy Chief Executive Officer of Mubadala Bio, and Mohamed El Dababy, President of GSK's International Central Region, during the Abu Dhabi Future Health Summit.
The collaboration will see IDS handling sales, marketing, distribution, and promotion of GSK's General Medicines portfolio, which includes over 20 medicines in the UAE. This partnership leverages IDS's extensive local market knowledge and capabilities alongside GSK's global scientific expertise, aiming to enhance local pharmaceutical capabilities and deliver sustained value to patients and healthcare providers in the region.
The alliance exemplifies the strategic advantages of collaboration between international healthcare leaders and national entities, aiming to achieve improved health outcomes within the UAE and potentially beyond.